Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China; Yunnan Key Laboratory of Panax notoginseng, Kunming University of Science and Technology, Kunming, 650500, China.
Leiden University-European Center for Chinese Medicine and Natural Compounds, Institute of Biology Leiden, Leiden University, Leiden, 2333BE, the Netherlands; SU Biomedicine B.V., Leiden, 2333BE, the Netherlands; Center for Drug Discovery & Technology Development of Yunnan Traditional Medicine, Kunming, 650217, China.
J Ethnopharmacol. 2022 Apr 24;288:114941. doi: 10.1016/j.jep.2021.114941. Epub 2022 Jan 7.
Panax notoginseng (PN) (Burk.) F. H. Chen is a medicinal herb used to treat blood disorders since ancient times, of which the steamed form exhibits the anti-anemia effect and acts with a "blood-tonifying" function according to the traditional use. However, its pharmacological effect and mechanism on alleviating renal anemia (RA) are still unclear.
The study aims to investigate the effect of steamed Panax notoginseng (SPN) to attenuate RA and its underlying mechanism based on the model of adenine-induced RA mice.
Seventy mice were randomly divided into seven groups of ten: the control group, model group, the erythropoietin (EPO) group, the Fufang E'jiao Jiang (FEJ) group, the high-dose steamed PN (H-SPN) group, the middle-dose steamed PN (M-SPN) group, and the low-dose steamed PN (L-SPN) group. The adenine induction RA model was applied to assess the "blood enriching" function of SPN. The blood routine indexes, erythrocyte fragility, pathologic morphology of kidney tissue and the expression levels of related cytokines and proteins in the mice were detected after 3-week administration with SPN and positive drugs.
Our study provided evidences that SPN could ameliorate RA. Compared with the control group, SPN could attenuate RA by significantly increasing the numbers of peripheral blood cells (p < 0.01), improving the erythrocyte fragility (p < 0.01), and restoring the expression of EPO mRNA in the kidneys and EPO receptor mRNA in bone marrow nucleated cells. The expression of TGF-β mRNA was declined and the expression of HGF mRNA was significantly increased in a dose-dependent way after the treatment of SPN. Additionally, the expression of Bcl-2 and Bcl-2/Bax ratio in the kidneys were significantly increased. In contrast, there was a highly significant decrease in the expression of Bax (p < 0.01), following SPN treatment.
SPN could alleviate RA by promoting the overall hematopoiesis and inhibiting the progress of renal injury in mice.
三七（PN）（Burk.）F. H. Chen 是一种自古以来用于治疗血液疾病的草药，其中蒸制形式具有抗贫血作用，并根据传统用途发挥“补血”作用。然而，其对缓解肾性贫血（RA）的药理作用和机制仍不清楚。
本研究旨在基于腺嘌呤诱导的 RA 小鼠模型，探讨蒸制三七（SPN）减轻 RA 的作用及其潜在机制。
将 70 只小鼠随机分为 7 组，每组 10 只：对照组、模型组、促红细胞生成素（EPO）组、复方阿胶浆（FEJ）组、高剂量蒸制 PN（H-SPN）组、中剂量蒸制 PN（M-SPN）组和低剂量蒸制 PN（L-SPN）组。应用腺嘌呤诱导 RA 模型评估 SPN 的“补血”功能。给药 3 周后，检测小鼠的血常规指标、红细胞脆性、肾脏组织病理形态以及相关细胞因子和蛋白的表达水平。
本研究提供了 SPN 可改善 RA 的证据。与对照组相比，SPN 可通过显著增加外周血白细胞数量（p<0.01）、改善红细胞脆性（p<0.01）、恢复肾脏 EPO mRNA 和骨髓有核细胞 EPO 受体 mRNA 的表达，从而减轻 RA。SPN 呈剂量依赖性降低 TGF-βmRNA 的表达，显著增加 HGF mRNA 的表达。此外，肾脏中 Bcl-2 和 Bcl-2/Bax 比值明显增加。相反，SPN 治疗后 Bax 的表达显著降低（p<0.01）。
SPN 可通过促进整体造血和抑制小鼠肾脏损伤的进展来缓解 RA。
